AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31313296 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg alone (reference)
Number of subjects: 11
Study 27723425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HP dispensed in prefilled trays (Opalescence Go 10%)
Number of subjects: 75
Study 27723425 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% HP (Pola Day) delivered in customized trays
Number of subjects: 75
Study 27723425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP delivered in customized trays (Opalescence PF 10%)
Number of subjects: 75
Study 26081765 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus structured counselling session by a registered dietitian with four follow-up telephone support sessions over four weeks.
Number of subjects: 0
Study 26081765 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 23393319 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center daily hemodialysis (6 days per week)
Number of subjects: 332
Study 23393319 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 days per week)
Number of subjects: 332
Study 23393319 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nocturnal hemodialysis (6 nights per week)
Number of subjects: 332
Study 23393319 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (6 days per week)
Number of subjects: 332
Study 21323269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8-mm MCCS
Number of subjects: 30
Study 21323269 — intervention group
Group type: COMPARATOR
Intervention: 2.2-mm MCCS
Number of subjects: 30
Study 18359280 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg dose of methylprednisolone (Group I)
Number of subjects: 40
Study 18359280 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dose of methylprednisolone (Group II)
Number of subjects: 40
Study 18359280 — intervention group
Group type: EXPERIMENTAL
Intervention: four 250 mg doses of methylprednisolone (Group III)
Number of subjects: 40
Study 18359280 — intervention group
Group type: EXPERIMENTAL
Intervention: four 500 mg doses of methylprednisolone (Group IV)
Number of subjects: 40
Study 18359280 — intervention group
Group type: COMPARATOR
Intervention: placebo (Group V)
Number of subjects: 40
Study 17324243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 0.625 mg (1.25 ml) for children aged > or =6 months to <1 year
Number of subjects: 58
Study 17324243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 1.25 mg (2.5 ml) for children aged > or =1 year to < or =2 years
Number of subjects: 58
Study 17324243 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine syrup 5 mg for adults
Number of subjects: 58
Study 17324243 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses of 1.0 mg for children aged > or =6 months to <1 year and 1.25 mg for children aged > or =1 year to < or =2 years
Number of subjects: 58
Study 17324243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 58
Study 14655041 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron 300 microg plus dexamethasone 20 mg
Number of subjects: 283
Study 14655041 — intervention group
Group type: COMPARATOR
Intervention: ramosetron 300 microg alone
Number of subjects: 283
Study 14655041 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron 100 microg once daily plus dexamethasone 8 mg twice daily
Number of subjects: 283
Study 14655041 — intervention group
Group type: COMPARATOR
Intervention: ramosetron 100 microg once daily
Number of subjects: 283
Study 11303724 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 0
Study 11303724 — intervention group
Group type: COMPARATOR
Intervention: PH
Number of subjects: 0
Study 11303724 — intervention group
Group type: COMPARATOR
Intervention: DIC
Number of subjects: 0
Study 9700710 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fast fluid attenuated inversion recovery (FLAIR) scans associated with enhanced MRI after the injection of a triple dose (TD) of gadolinium (Gd)
Number of subjects: 13
Study 9700710 — intervention group
Group type: COMPARATOR
Intervention: Monthly dual‐echo spin‐echo (SE) and enhanced magnetic resonance imaging (MRI) after the injection of a standard dose (SD) of gadolinium (Gd)
Number of subjects: 13
Study 7924370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25% racemic epinephrine
Number of subjects: 28
Study 7924370 — intervention group
Group type: COMPARATOR
Intervention: 1% l-epinephrine
Number of subjects: 28
Study 2572260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (a selective beta 1‐adrenoceptor antagonist)
Number of subjects: 8
Study 2572260 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (a beta 1‐adrenoceptor partial agonist with 43% agonist activity)
Number of subjects: 8
Study 2572260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1097153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 0
Study 1097153 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 31615795 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy (VATS)
Number of subjects: 0
Study 31615795 — intervention group
Group type: COMPARATOR
Intervention: Conventional open lobectomy
Number of subjects: 0
Study 28191861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 0
Study 28191861 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 0
Study 25627259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation with relaxation (six sessions during pregnancy, one after childbirth, n = 131)
Number of subjects: 371
Study 25627259 — intervention group
Group type: COMPARATOR
Intervention: Surveillance and referral on demand (n = 240)
Number of subjects: 371
Study 23601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost (Group 1)
Number of subjects: 30
Study 23601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved latanoprost (Group 2)
Number of subjects: 30
Study 23601909 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of latanoprost (Group 3)
Number of subjects: 30
Study 23601909 — intervention group
Group type: COMPARATOR
Intervention: Physiological buffered saline solution (Group 4)
Number of subjects: 30
Study 21843921 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab plus chemotherapy
Number of subjects: 235
Study 21843921 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 235
Study 19860363 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women (Group I)
Number of subjects: 80
Study 19860363 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women (Group II)
Number of subjects: 80
Study 19860363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correlation with serum E2 levels
Number of subjects: 80
Study 16671973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing educational intervention including standardized health advice, two booklets, a no smoking sticker, and a telephone reminder
Number of subjects: 1483
Study 16671973 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1483
Study 15001604 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplement (0.75 g/kg)
Number of subjects: 32
Study 15001604 — intervention group
Group type: COMPARATOR
Intervention: Low protein supplement (0.04 g/kg)
Number of subjects: 32
Study 15273093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitrogen oxides (sodium nitrite 6%, citric acid monohydrate 9%) applied daily for 6 weeks
Number of subjects: 37
Study 15273093 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied daily for 6 weeks
Number of subjects: 37
Study 15273093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received nitrogen oxide-generating creams for the second 6 weeks
Number of subjects: 37
Study 10994918 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (16 mL x kg(‐1) of a drink containing 7.6 g x 100 mL(‐1) carbohydrate)
Number of subjects: 43
Study 10994918 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (indistinguishable noncaloric placebo drink)
Number of subjects: 43
Study 10994918 — intervention group
Group type: EXPERIMENTAL
Intervention: Not told (neither carbohydrate nor placebo information)
Number of subjects: 43
Study 9383124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% of Wmax for 2 hours
Number of subjects: 30
Study 9383124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna for 2 hours
Number of subjects: 30
Study 9383124 — intervention group
Group type: COMPARATOR
Intervention: Rest for 2 hours
Number of subjects: 30
Study 1287378 — intervention group
Group type: EXPERIMENTAL
Intervention: Double stopcock technique (DST)
Number of subjects: 12
Study 1287378 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock (HPL)
Number of subjects: 12
Study 1287378 — intervention group
Group type: COMPARATOR
Intervention: Angiocath with obturator (AOB)
Number of subjects: 12
Study 1287378 — intervention group
Group type: COMPARATOR
Intervention: Direct venipuncture (DVP)
Number of subjects: 12
Study 3546153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg (single oral dose)
Number of subjects: 43
Study 3546153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg b.i.d. (seven-day course)
Number of subjects: 43
Study 3546153 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg b.i.d. (seven-day course)
Number of subjects: 43
Study 2899536 — intervention group
Group type: COMPARATOR
Intervention: sulphasalazine 2 g daily
Number of subjects: 61
Study 2899536 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 800 mg daily
Number of subjects: 61
Study 2899536 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 2.4 g daily
Number of subjects: 61
Study 31142254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia (abnormal lipid profiles)
Number of subjects: 378
Study 31142254 — intervention group
Group type: COMPARATOR
Intervention: Normal lipid profiles
Number of subjects: 378
Study 28489465 — intervention group
Group type: EXPERIMENTAL
Intervention: LED group (treadmill training with phototherapy)
Number of subjects: 30
Study 28489465 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (treadmill training only)
Number of subjects: 30
Study 28489465 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (no physical training or phototherapy)
Number of subjects: 30
Study 26517214 — intervention group
Group type: EXPERIMENTAL
Intervention: bromazepam (6 mg)
Number of subjects: 15
Study 26517214 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil (200 mg)
Number of subjects: 15
Study 26517214 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 23276322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (nine-session substance abuse prevention program, delivered online)
Number of subjects: 108
Study 23276322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 108
Study 23276322 — intervention group
Group type: COMPARATOR
Intervention: Control (test-only control arm)
Number of subjects: 108
Study 23276322 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study 21996071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape-OCA combination
Number of subjects: 216
Study 21996071 — intervention group
Group type: COMPARATOR
Intervention: OCA-only
Number of subjects: 216
Study 19013741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational telephone support from a peer supporter
Number of subjects: 231
Study 19013741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational telephone support from a diabetes specialist nurse (DSN)
Number of subjects: 231
Study 19013741 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 231
Study 17399972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg inhalation
Number of subjects: 30
Study 17399972 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 30
Study 17399972 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 30
Study 16132321 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib, 200 mg by mouth
Number of subjects: 60
Study 16132321 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib, 50 mg by mouth
Number of subjects: 60
Study 16132321 — intervention group
Group type: EXPERIMENTAL
Intervention: diclophenac sodium, 75 mg intramuscularly
Number of subjects: 60
Study 16132321 — intervention group
Group type: COMPARATOR
Intervention: placebo, pill
Number of subjects: 60
Study 11514125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peeling
Number of subjects: 0
Study 11514125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peeling at concentrations of 35%, 50%, or 70%
Number of subjects: 0
Study 9505741 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway auscultation technique using a stethoscope
Number of subjects: 100
Study 7777216 — intervention group
Group type: EXPERIMENTAL
Intervention: Various nursing care delivery models and management interventions
Number of subjects: 37
Study 7777216 — intervention group
Group type: EXPERIMENTAL
Intervention: All initiatives in aggregate
Number of subjects: 37
Study 7777216 — intervention group
Group type: EXPERIMENTAL
Intervention: Each of the five types of initiatives separately
Number of subjects: 37
Study 7777216 — intervention group
Group type: EXPERIMENTAL
Intervention: All initiatives taken as a group
Number of subjects: 37
Study 7777216 — intervention group
Group type: EXPERIMENTAL
Intervention: Units that implemented reorganization, computer, and education initiatives
Number of subjects: 37
Study 3128113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm single dose)
Number of subjects: 58
Study 3128113 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 gm doses)
Number of subjects: 58
Study 31033904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycling at moderate intensity)
Number of subjects: 32
Study 31033904 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction
Number of subjects: 32
Study 28751136 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered eyes
Number of subjects: 94
Study 28751136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine sounds
Number of subjects: 94
Study 28751136 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 25986572 — intervention group
Group type: EXPERIMENTAL
Intervention: GP triage management system
Number of subjects: 20990
Study 25986572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse triage management system
Number of subjects: 20990
Study 25986572 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20990
Study 25986572 — intervention group
Group type: EXPERIMENTAL
Intervention: All trial arms
Number of subjects: 20990
Study 23090004 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone + Ulinastatin (Risperidone 1 mg orally 30-60 min before ERCP, Ulinastatin 150000 U intravenously for 10 min prior to ERCP)
Number of subjects: 226
Study 23090004 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin (150000 U intravenously for 10 min prior to ERCP)
Number of subjects: 226
Study 23090004 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone + Ulinastatin
Number of subjects: 226
Study 23090004 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin
Number of subjects: 226
Study 21084763 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/day × 6 days)
Number of subjects: 20
Study 21084763 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (1.75 mg/day × 1 day)
Number of subjects: 20
Study 19687181 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (N=117)
Number of subjects: 172
Study 19687181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=55)
Number of subjects: 172
Study 16415641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 3000
Study 16415641 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention
Number of subjects: 3000
Study 16415641 — intervention group
Group type: COMPARATOR
Intervention: Reperfusion therapy with fibrinolytic agents
Number of subjects: 3000
Study 15383186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propionyl-L-carnitine (PLC) 2 g/day plus sildenafil 50 mg twice weekly (Group 1)
Number of subjects: 40
Study 15383186 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil alone (Group 2)
Number of subjects: 40
Study 11725599 — intervention group
Group type: COMPARATOR
Intervention: Level walking
Number of subjects: 8
Study 11725599 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair ascent
Number of subjects: 8
Study 11725599 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair descent
Number of subjects: 8
Study 9558831 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT (lymphatic and splenic pump) three times per week for 2 weeks after each vaccination
Number of subjects: 39
Study 9558831 — intervention group
Group type: COMPARATOR
Intervention: Control (vaccine only, no OMT)
Number of subjects: 39
Study 9558831 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT (lymphatic and splenic pump)
Number of subjects: 39
Study 7928931 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine, 0.5 mg twice daily
Number of subjects: 30
Study 7928931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7928931 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 30
Study 3034757 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (chronic converting enzyme inhibition)
Number of subjects: 10
Study 3034757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HIV stigma
Number of subjects: 234
Study 30932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted stigma (between-subject)
Number of subjects: 234
Study 30932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted stigma (within-subject)
Number of subjects: 234
Study 30932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 234
Study 30932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 234
Study 28300857 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 836
Study 25886822 — intervention group
Group type: EXPERIMENTAL
Intervention: Community In-Reach and Care Transition (CIRACT) service
Number of subjects: 240
Study 25886822 — intervention group
Group type: COMPARATOR
Intervention: Traditional Hospital Based rehabilitation (THB-Rehab)
Number of subjects: 240
Study 25886822 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRACT service
Number of subjects: 240
Study 25886822 — intervention group
Group type: COMPARATOR
Intervention: CIRACT service and THB-Rehab
Number of subjects: 240
Study 23379725 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoflex tube
Number of subjects: 130
Study 23379725 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube with stylet
Number of subjects: 130
Study 21341146 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block with 0.5% levobupivacaine (30 mL) followed by interscalene infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Number of subjects: 60
Study 21341146 — intervention group
Group type: COMPARATOR
Intervention: Subacromial infusion: 0.125% levobupivacaine 5 mL/h basal infusion, 5 mL bolus dose, 20 min lockout time.
Number of subjects: 60
Study 19639303 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Spectrum Treatment (BST) with extended Naltrexone (NTX)
Number of subjects: 174
Study 19639303 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) with extended Naltrexone (NTX)
Number of subjects: 174
Study 19639303 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Spectrum Treatment (BST) with short Naltrexone (NTX)
Number of subjects: 174
Study 19639303 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) with short Naltrexone (NTX)
Number of subjects: 174
Study 19639303 — intervention group
Group type: COMPARATOR
Intervention: Placebo after initial treatment
Number of subjects: 174
Study 17664202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction of 0.40 increased to 0.60 during rewarming
Number of subjects: 90
Study 17664202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction of 0.40 and 0.50
Number of subjects: 90
Study 17664202 — intervention group
Group type: COMPARATOR
Intervention: Inspired oxygen fraction of 0.35 and 0.45
Number of subjects: 90
Study 15555666 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 534
Study 15555666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 11783837 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 0
Study 11783837 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 0
Study 11783837 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study 11783837 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxants
Number of subjects: 0
Study 11783837 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitryptiline, ondansetron, zoldipem, growth hormone
Number of subjects: 0
Study 11783837 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs, malic acid with magnesium, calcitonin injections, s-adenyl-L-methionine
Number of subjects: 0
Study 11783837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan
Number of subjects: 0
Study 9131679 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% long‐chain triacylglycerols (LCT) with 55% of linoleic acid and 7% of alpha linolenic acid in 100 g of emulsion
Number of subjects: 0
Study 9131679 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% medium‐chain triacyglycerols (MCT) and LCT with 26% of linoleic acid and 4% of alpha linolenic acid in 100 g of emulsion
Number of subjects: 0